Michael Halstead Intra Cellular Therapies, Inc. (ITCI) insider trading activity

ITCI Quotes by TradingView

Michael Halstead is EVP and General Counsel of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 0 shares of ITCI, which is worth approximately $0. The most recent transaction as insider was on Mar 11, 2024, when has been sold 7,345 shares (Common Stock) at a price of $66.26 per share, resulting in proceeds of $486,679. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Michael Halstead Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 11 2024
SELL
Open market or private sale
$486,679 $66.26 p/Share
7,345 Reduced 100.0%
0 Common Stock
Mar 10 2024
BUY
Exercise of conversion of derivative security
-
7,345 Added 50.0%
7,345 Common Stock
Mar 07 2024
SELL
Open market or private sale
$872,884 $66.47 p/Share
13,132 Reduced 100.0%
0 Common Stock
Mar 06 2024
BUY
Exercise of conversion of derivative security
-
13,132 Added 50.0%
13,132 Common Stock
Feb 26 2024
SELL
Open market or private sale
$548,745 $69.4 p/Share
7,907 Reduced 100.0%
0 Common Stock
Feb 23 2024
BUY
Exercise of conversion of derivative security
-
7,907 Added 50.0%
7,907 Common Stock
Feb 02 2024
SELL
Open market or private sale
$791,892 $66.77 p/Share
11,860 Reduced 100.0%
0 Common Stock
Feb 01 2024
BUY
Grant, award, or other acquisition
-
11,860 Added 50.0%
11,860 Common Stock
Jan 11 2024
SELL
Open market or private sale
$3,353,499 $67.07 p/Share
50,000 Reduced 100.0%
0 Common Stock
Jan 11 2024
BUY
Exercise of conversion of derivative security
$917,000 $18.34 p/Share
50,000 Added 50.0%
50,000 Common Stock
Nov 13 2023
SELL
Open market or private sale
$2,684,500 $53.69 p/Share
50,000 Reduced 100.0%
0 Common Stock
Nov 13 2023
BUY
Exercise of conversion of derivative security
$705,000 $14.1 p/Share
50,000 Added 50.0%
50,000 Common Stock
Mar 13 2023
SELL
Open market or private sale
$327,322 $44.57 p/Share
7,344 Reduced 100.0%
0 Common Stock
Mar 10 2023
SELL
Open market or private sale
$716,104 $42.86 p/Share
16,708 Reduced 100.0%
0 Common Stock
Mar 10 2023
BUY
Exercise of conversion of derivative security
-
7,344 Added 50.0%
7,344 Common Stock
Mar 09 2023
BUY
Grant, award, or other acquisition
-
16,708 Added 50.0%
16,708 Common Stock
Feb 24 2023
SELL
Open market or private sale
$371,819 $47.03 p/Share
7,906 Reduced 100.0%
0 Common Stock
Feb 23 2023
BUY
Exercise of conversion of derivative security
-
7,906 Added 50.0%
7,906 Common Stock
Feb 21 2023
SELL
Open market or private sale
$534,894 $48.02 p/Share
11,139 Reduced 100.0%
0 Common Stock
Feb 18 2023
BUY
Exercise of conversion of derivative security
-
11,139 Added 50.0%
11,139 Common Stock
Dec 01 2022
SELL
Open market or private sale
$2,685,500 $53.71 p/Share
50,000 Reduced 100.0%
0 Common Stock
Dec 01 2022
BUY
Exercise of conversion of derivative security
$773,500 $15.47 p/Share
50,000 Added 50.0%
50,000 Common Stock
Feb 24 2022
SELL
Open market or private sale
$411,112 $52.0 p/Share
7,906 Reduced 100.0%
0 Common Stock
Feb 23 2022
BUY
Exercise of conversion of derivative security
-
7,906 Added 50.0%
7,906 Common Stock
Feb 22 2022
SELL
Open market or private sale
$616,321 $55.33 p/Share
11,139 Reduced 100.0%
0 Common Stock
MH

Michael Halstead

EVP and General Counsel
New York, NY

Track Institutional and Insider Activities on ITCI

Follow Intra-Cellular Therapies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

News

Receive news related to Intra-Cellular Therapies, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ITCI